Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


09 abril 2013

Renal denervation should not be part of routine clinical practice, delegates say

Vascular News

At today’s CX Renal Denervation Session Great Debate, delegates voted 3:1 against the motion that renal denervation should be used routinely to treat hypertension. As all of the speakers, regardless of which side of the debate they were, agreed that renal denervation should only be used to treat patients with resistant hypertension, the real focus of the debate centred on what was meant by the word “routine”.

09 abril 2013

CT is the best imaging modality for deep vein thrombosis

Vascular News

Gerard O Sullivan, Galway, Ireland, spoke in the Venous Challenges sessions on Tuesday 9 April about imaging for iliac deep vein thrombosis and the best modalities to use. He told delegates that computed tomography pulmonary angiography (CTPA) and CT venography are his preferred modalities.

13 marzo 2013

Knowing the long-term benefits of renal denervation is a priority

Interventional News. By Jan Staessen

Hypertension affects an estimated 20% to 30% of the world’s adult population. Despite the availability of numerous safe and effective pharmacological therapies, including single pill combinations of two to three drugs, the percentage of patients achieving adequate blood pressure control meeting guideline targets remains low.

04 marzo 2013

Myths about interventional management of vascular malformations: general approach and diagnosis

Interventional News. By Ahmad Alomari

Vascular anomalies can be broadly classified into vascular tumours (eg. infantile haemangioma) and vascular malformations. The two main categories of vascular malformations are slow-flow (venous, lymphatic and capillary malformations) or fast-flow (arteriovenous malformations and fistulas). The interventional management of vascular malformations is the primary minimally-invasive therapy which largely replaced the surgical approach. The use of accurate terminology to describe this heterogenous, occasionally overlapping group of disorders is crucial for proper management and research. Unfortunately, despite the major improvement in the clinical, genetic and therapeutic management of vascular anomalies, myths and misconceptions about the diagnosis and management of these anomalies continue to be surprisingly pervasive with frequent serious consequences.

28 marzo 2013

High-intensity focused ultrasound may be an alternative renal denervation approach

Interventional News

An animal study, published ahead of print in the Journal of the American College of Cardiology, indicates that renal denervation delivered through high-intensity focused ultrasound (HIFU) extracorpeal renal denervation may be an alternative approach to managing resistant hypertension as it is associated with blood pressure reduction without significant morbidity or mortality.

25 marzo 2013

Asocian uso de estatinas con menor riesgo de cáncer hepático en pacientes con hepatitis C

Reuters Health

Un estudio de Taiwán sugiere que quienes padecen hepatitis C crónica tendrían menos riesgo de desarrollar cáncer hepático si toman fármacos para reducir el colesterol. Esto no prueba que las estatinas previenen el cáncer y un científico ajeno al estudio dice que no hay motivo suficiente para recomendar el uso de esos fármacos para evitar el cáncer de hígado.

25 marzo 2013

Cuando se extirpa el útero conviene conservar los ovarios

Reuters Health

Aunque durante una histerectomía también se suelen extirpar los ovarios, un nuevo estudio sugiere que dejarlos intactos sería más beneficioso. Un equipo halló que la extirpación ovárica reducía el riesgo de cáncer de ovario, pero a la vez que potenciaba el riesgo de morir por otras causas más comunes.

27 marzo 2013

SEATTLE II trial completes enrolment in the USA

Vascular News

The SEATTLE II study, which will investigate the safety and efficacy of ultrasound accelerated thrombolysis with the EkoSonic Endovascular System (EKOS Corporation) for the treatment of massive and submassive pulmonary embolism, has completed enrolment. SEATTLE II is a 150-patient, single-arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive pulmonary embolism.

21 marzo 2013

Se implantan filtros para coágulos sanguíneos sin respaldo científico

Reuters Health

Un nuevo estudio revela que algunos hospitales implantan filtros en los vasos sanguíneos de más de un tercio de sus pacientes que desarrollan coágulos que podrían llegar a los pulmones, pese a que aún no existen pruebas científicas de que el dispositivo salve vidas.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.